[go: up one dir, main page]

HUE037554T2 - Kémiailag módosított heparinszármazékok alkalmazása sarlósejtes betegségben - Google Patents

Kémiailag módosított heparinszármazékok alkalmazása sarlósejtes betegségben

Info

Publication number
HUE037554T2
HUE037554T2 HUE12859384A HUE12859384A HUE037554T2 HU E037554 T2 HUE037554 T2 HU E037554T2 HU E12859384 A HUE12859384 A HU E12859384A HU E12859384 A HUE12859384 A HU E12859384A HU E037554 T2 HUE037554 T2 HU E037554T2
Authority
HU
Hungary
Prior art keywords
chemically modified
sickle cell
cell disease
heparin derivatives
modified heparin
Prior art date
Application number
HUE12859384A
Other languages
English (en)
Inventor
Hans-Peter Ekre
Anna Leitgeb
Mats Wahlgren
Dagmar Pikas
Original Assignee
Modus Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modus Therapeutics Ab filed Critical Modus Therapeutics Ab
Publication of HUE037554T2 publication Critical patent/HUE037554T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE12859384A 2011-12-19 2012-12-19 Kémiailag módosított heparinszármazékok alkalmazása sarlósejtes betegségben HUE037554T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE2011/051538 WO2013095215A1 (en) 2011-12-19 2011-12-19 Low anticoagulant heparins

Publications (1)

Publication Number Publication Date
HUE037554T2 true HUE037554T2 (hu) 2018-09-28

Family

ID=48668926

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE12859384A HUE037554T2 (hu) 2011-12-19 2012-12-19 Kémiailag módosított heparinszármazékok alkalmazása sarlósejtes betegségben
HUE12860938A HUE037555T2 (hu) 2011-12-19 2012-12-19 Alacsony alvadásgátló hatású heparinok

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE12860938A HUE037555T2 (hu) 2011-12-19 2012-12-19 Alacsony alvadásgátló hatású heparinok

Country Status (27)

Country Link
US (2) US9480701B2 (hu)
EP (2) EP2794667B1 (hu)
JP (2) JP6703806B2 (hu)
CN (1) CN104053675B (hu)
AU (1) AU2012354226B2 (hu)
BR (1) BR112014014673B1 (hu)
CA (2) CA2856918C (hu)
CY (2) CY1120197T1 (hu)
DK (2) DK2794667T3 (hu)
ES (2) ES2669055T3 (hu)
HK (2) HK1199893A1 (hu)
HR (2) HRP20180725T1 (hu)
HU (2) HUE037554T2 (hu)
IL (1) IL232903A (hu)
IN (1) IN2014MN01056A (hu)
MX (1) MX358439B (hu)
MY (1) MY170069A (hu)
NO (2) NO2794667T3 (hu)
PH (1) PH12014501387B1 (hu)
PL (2) PL2794666T3 (hu)
PT (2) PT2794667T (hu)
RS (2) RS57214B1 (hu)
SI (2) SI2794667T1 (hu)
SM (2) SMT201800218T1 (hu)
TN (2) TN2014000236A1 (hu)
WO (3) WO2013095215A1 (hu)
ZA (1) ZA201403654B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014014454B1 (pt) 2011-12-19 2021-03-09 Dilafor Ab glicosaminoglicanos não anti-coagulativos compreendendo unidade de dissacarìdo repetida e seus usos médicos
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
EP2965764A1 (en) * 2014-07-11 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
US20170049862A1 (en) * 2014-04-30 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
CA3097047A1 (en) * 2018-04-13 2019-10-17 University Of Virginia Patent Foundation Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels
CN109481692A (zh) * 2018-11-30 2019-03-19 东南大学 一种青蒿琥酯肝素衍生物及其药物组合物和应用
WO2023239711A1 (en) * 2022-06-06 2023-12-14 Ihp Therapeutics Inc. Chemically modified heparin
CN115448994B (zh) * 2022-09-28 2023-08-01 山东大学 一种可中和抗凝低分子量肝素及其制备方法和应用
WO2024072942A2 (en) * 2022-09-29 2024-04-04 Adora Animal Health Corporation Skin penetrating formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
GB2625581A (en) 2022-12-21 2024-06-26 Modus Therapeutics Ab New medical use
WO2024170746A1 (en) 2023-02-17 2024-08-22 Modus Therapeutics Ab New medical use of sevuparin in the treatment of endotoxemia
GB2627263A (en) * 2023-02-17 2024-08-21 Modus Therapeutics Ab New medical use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
ES2054975T3 (es) * 1988-10-07 1994-08-16 Hoechst Ag Composiciones antimalaricas que emplean quinidina, artemisinina y sus derivados.
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) * 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
WO1994008595A1 (en) 1992-10-13 1994-04-28 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
GB2299998B (en) * 1995-03-31 1997-03-26 Hamilton Civic Hospitals Res Compositions for inhibiting thrombogenesis
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
US6569840B1 (en) * 1997-11-20 2003-05-27 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
EP1059304B1 (en) 1998-02-26 2006-04-26 Seikagaku Corporation Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
US6492503B1 (en) * 1998-07-31 2002-12-10 Seikagaku Corporation Glycosaminoglycan and drug compositions containing the same
CN1371391A (zh) * 1999-06-30 2002-09-25 汉密尔顿市医院研究发展有限公司 抑制凝血相关凝血因子的肝素成分
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
CA2422059C (en) * 2000-09-12 2012-05-15 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
AU2003230985A1 (en) 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
DK1758557T3 (da) * 2004-05-11 2011-10-24 Egalet Ltd Kvældbar doseringsform omfattende gellangummi
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
EP1906975A4 (en) 2005-07-22 2010-10-06 Trf Pharma Inc METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE
MX2008000974A (es) * 2005-07-22 2008-03-27 Univ California Composiciones de heparina e inhibicion de selectina.
CA2652205A1 (en) * 2006-05-25 2007-12-06 Mallik Sundaram Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (en) * 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
JP5758797B2 (ja) * 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
CN102105427A (zh) * 2008-07-25 2011-06-22 阿尔法制药有限公司 粒度直径范围(D90)为大于3μm至约10μm的阿托伐醌
WO2010121196A1 (en) 2009-04-16 2010-10-21 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
US20120108538A1 (en) * 2009-06-30 2012-05-03 James Beeson Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
BR112014014454B1 (pt) 2011-12-19 2021-03-09 Dilafor Ab glicosaminoglicanos não anti-coagulativos compreendendo unidade de dissacarìdo repetida e seus usos médicos
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
SG11201406119WA (en) 2012-03-26 2014-11-27 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor
NZ631279A (en) 2012-03-26 2016-06-24 Dilafor Ab Method for treatment of labor arrest

Also Published As

Publication number Publication date
TN2014000237A1 (en) 2015-09-30
RS57213B1 (sr) 2018-07-31
PT2794666T (pt) 2018-05-09
HK1200471A1 (en) 2015-08-07
MY170069A (en) 2019-07-03
MX2014006956A (es) 2014-10-17
CY1120197T1 (el) 2018-12-12
CA2856477A1 (en) 2013-06-27
SMT201800217T1 (it) 2018-05-02
SMT201800218T1 (it) 2018-05-02
NO2794667T3 (hu) 2018-07-21
SI2794667T1 (en) 2018-06-29
NO2794666T3 (hu) 2018-07-21
RS57214B1 (sr) 2018-07-31
BR112014014673B1 (pt) 2021-02-17
US20140364369A1 (en) 2014-12-11
NZ625096A (en) 2016-07-29
WO2013095215A1 (en) 2013-06-27
SI2794666T1 (en) 2018-06-29
EP2794666A4 (en) 2015-07-22
EP2794667A1 (en) 2014-10-29
PL2794666T3 (pl) 2018-08-31
JP2018154848A (ja) 2018-10-04
US9480702B2 (en) 2016-11-01
EP2794666B1 (en) 2018-02-21
EP2794666A1 (en) 2014-10-29
PL2794667T3 (pl) 2018-09-28
HRP20180726T1 (hr) 2018-06-15
TN2014000236A1 (en) 2015-09-30
ZA201403654B (en) 2017-08-30
AU2012354226A1 (en) 2014-06-05
IN2014MN01056A (hu) 2015-05-01
ES2669055T3 (es) 2018-05-23
WO2013095276A1 (en) 2013-06-27
EP2794667A4 (en) 2015-07-22
JP6703806B2 (ja) 2020-06-03
EP2794667B1 (en) 2018-02-21
PH12014501387A1 (en) 2014-09-22
BR112014014673A8 (pt) 2017-07-04
IL232903A (en) 2017-02-28
CA2856918A1 (en) 2013-06-27
JP2015500387A (ja) 2015-01-05
HK1199893A1 (en) 2015-07-24
MX358439B (es) 2018-08-21
PT2794667T (pt) 2018-05-16
WO2013095277A1 (en) 2013-06-27
ES2668273T3 (es) 2018-05-17
HRP20180725T1 (hr) 2018-06-29
CN104053675A (zh) 2014-09-17
AU2012354226B2 (en) 2017-01-12
US20150031638A1 (en) 2015-01-29
CN104053675B (zh) 2016-10-12
IL232903A0 (en) 2014-07-31
DK2794666T3 (en) 2018-04-23
PH12014501387B1 (en) 2014-09-22
CY1120194T1 (el) 2018-12-12
HUE037555T2 (hu) 2018-09-28
CA2856477C (en) 2017-06-27
US9480701B2 (en) 2016-11-01
BR112014014673A2 (pt) 2017-06-13
DK2794667T3 (en) 2018-04-23
CA2856918C (en) 2017-07-04

Similar Documents

Publication Publication Date Title
HUE037554T2 (hu) Kémiailag módosított heparinszármazékok alkalmazása sarlósejtes betegségben
EP2768423A4 (en) OPHTHALMIC STRUCTURE
IL229313A0 (en) Rods for use in smoking articles
DK3366775T3 (da) Modificerede rnai-midler
BR112013023241A8 (pt) melhorias para entidades biológicas imobilizadas
EP2673344A4 (en) STABLE BIO OIL
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
BR112013032887A2 (pt) cateter
FI20105825A0 (fi) Veriryhmästatuksen käyttö III
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
EP2682082A4 (en) Tampon applicator
EP2794665A4 (en) NON-ANTIKOAGULATIVE GLYCOSAMINOGLYCANES WITH RECYCLING DISACCHARIN UNIT AND ITS MEDICAL USE
EP3701800C0 (en) USE
BR112014015814A2 (pt) fralda descartável
EP2714975A4 (en) ELASTIC FABRIC
BR112014012223A2 (pt) fralda descartável
BR112014009761A2 (pt) composição oftálmica
EP2794550A4 (en) OPHTHALMIC FORMULATION
PL2726442T5 (pl) Modyfikowane aminokarboksylany o ulepszonej trwałości podczas przechowywania i podatność na obróbkę
DK2590565T3 (da) Blodprøvetagning
HK1197976A1 (zh) 多段式發煙製品
CO6842018A2 (es) Heterociclicos microbiocidas
BR112014012225A2 (pt) fralda descartável
BR112014010432A2 (pt) uso médico
EP2687212A4 (en) DRUG